The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

The US Food and Drug Administration (FDA) has approved Eisai and Biogen’s Supplemental Biologics License Application for once ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

Recent health news includes significant developments such as Akero Therapeutics' promising liver disease drug, potential ...

Japanese pharmaceutical company Eisai Co and U.S. firm Biogen Inc said Monday that a jointly developed Alzheimer's drug has been approved for continuous use for people with early stages of the disease ...

Biogen Inc. (BIIB) saw its stock climb 1.7% on Monday afternoon, reaching a nearly two-week high following positive ...

The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...

Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...